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Background
OPTIMA has an adaptive design seeking to advance
development of personalised medicine in breast cancer
by assessing the value of multi-parameter tests, such as
Oncotype DX, in a UK population of intermediate risk.
Methods
OPTIMA prelim, the feasibility phase, aims to recruit 300
patients to evaluate performance and health-economics of
a number of multi-parameter tests to identify test(s) to be
used in the main trial and to establish the acceptability to
patients and clinicians of randomisation. Patients are ran-
domised to the standard arm or to the “test-directed treat-
ment” arm according to the result of Oncotype DX test.
The decision to roll forward into the main trial will be
determined by the willingness of patients to be rando-
mised, concordance and cost of the multi-parameter tests.
Cost-effectiveness models will be based on the model
developed in preparation for the OPTIMA trial, updated
with contemporary evidence from the feasibility study and
appropriate external data, e.g. the Ontario OncotypeDX
field evaluation (prospective cohort study).
Results
OPTIMA prelim opened in Sept 2012 and has 56 patients
registered (46 randomised). TSC and DMEC agreed deci-
sion rules and encouraged external collaboration to pro-
vide additional confidence and power for any decisions.
Conclusions
The success of OPTIMA relies on the integration of a
multi-disciplinary team of methodologists, clinical experts
and patients at all stages of the trial. The complexities of
using adaptive design methodology and decision making
to roll forward into the main trial are challenging but pro-
vide the most efficient use of patients and costs.
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